Table 2.
Adverse events n (%)
| Variables | Hypersensitivity | Pancreatitis | GI | Leucopenia | Hepatotoxicity | Infection |
| patients | 25 (7.1) | 22 (6.2) | 19 (5.4) | 13 (3.7) | 12 (3.4) | 4 (1.1) |
| Gender | ||||||
| Males | 16 (64.0) | 9 (40.9) | 7 (36.8) | 4 (30.8) | 4 (33.3) | 2 (50.0) |
| Females | 9 (36.0) | 13 (59.1) | 12 (63.2) | 9 (69.2) | 8 (66.7) | 2 (50.0) |
| Age at thiopurine (yr) | 37.6 (32.3, 47.9) | 43.9 (32.2, 48.8) | 26.5 (22.8, 47.1) | 29.6 (23.6, 47.7) | 49 (41.8, 57.9) | 24.3 (19.3, 27.1) |
| Time from prescription to withdrawal of thiopurine (d) | 31 (29.0, 65.0) | 29 (14.5, 30.0) | 17 (7.0, 26.0) | 347.5 (159.0, 866.0) | 51 (30.0, 70,0) | 1907 (603.0, 2718.0) |
| AZA dose (mg/kg) | 2.2 (1.6, 2.4) | 2.3 (2.0, 2.4) | 2 (1.7, 2.2) | 1.6 (0.8, 2.3) | 1.3 (0.8, 2.0) | 2.1 (2.0, 3.1) |
Main reasons leading to discontinuation of thiopurine therapy in 351 patients due to an adverse event. No multiple reasons were recorded. Data are given as median and IQR unless otherwise stated. Other (n = 15, 13.6%) causes for discontinuation were alopecia (n = 3), photosensitivity (n = 1), basal cell carcinoma (n = 2), mood disturbance (n = 1), syncopal episodes (n = 1), fatigue (n = 1), headache (n = 1), eye problems (n = 1) and unknown (n = 4). AZA: Azathioprine; IQR: Interquartile range; GI: Gastrointestinal intolerance.